Evoq Remedies Ltd (EVOQ) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Evoq Remedies Ltd on NSE and BSE, with an AI summary of each filing.
Approval of Extension of time for holding 16th Annual General Meeting for the Financial Year ended 31st March, 2026
Annual General Meeting · 02 Oct 2026, 12:04 am
Corporate Insolvency Resolution Process (CIRP) - Admission of application by Tribunal
Others (Uncategorized) · 11 Jun 2026, 10:45 pm
Evoq Remedies Admitted into Corporate Insolvency Resolution Process The NCLT Ahmedabad bench admitted Evoq Remedies into Corporate Insolvency Resolution Process (CIRP) via an order on 9th Jun'26. The application was filed by operational creditor M/s. Harbhole Agrotech under Section 9 of the IBC, 2016, over a default of Rs 1.95 crore. The default pertains to an advance payment for goods that were neither supplied nor refunded, with the default date cited as 1st Sep'25. Ms. Dipti Narayan Mundra has been appointed as the Interim Resolution Professional (IRP).
Corporate Insolvency Resolution process (CIRP) - Admission of application by Tribunal
Others (Uncategorized) · 10 Jun 2026, 11:41 pm
Evoq Remedies Faces Insolvency Proceedings from Operational Creditor Evoq Remedies Ltd. informed exchanges on 10th Jun'26 that an operational creditor, M/s. Harbhole Agrotech, has filed for insolvency proceedings against the company. The application, filed under Section 9 of the Insolvency and Bankruptcy Code, 2016, was submitted to the National Company Law Tribunal in Ahmedabad on 20th Apr'26. This action initiates a Corporate Insolvency Resolution Process against Evoq Remedies, posing a significant risk to the company's financial stability and operational continuity.
Submission of Integrated Financial Results for the Half year and Year ended on 31st March, 2026
Others (Uncategorized) · 31 May 2026, 1:14 am
Evoq Remedies FY26 Audit Flags Going Concern Risk and Governance Lapses Evoq Remedies reported a net loss of ₹23.99 lakhs for FY26 versus a profit of ₹8.82 lakhs in FY25. The auditor issued a qualified opinion, citing a material uncertainty related to its going concern status due to cash losses, curtailed operations, and persistent statutory defaults. Key qualifications include non-compliance on related-party loans of ₹670.26 lakhs, unconfirmed debtor balances of ₹385.46 lakhs, and unconfirmed supplier advances of ₹1,251.18 lakhs. The company also faces a SEBI investigation and contingent liabilities from tax demands.
Appointment of Secretarial Auditor of the Company for FY 2025-26.
Change in Auditor · 31 May 2026, 1:12 am
Evoq Remedies FY26 Auditor's Report Flags Going Concern & Governance Lapses On 30th May'26, Evoq Remedies' Board approved FY26 results and appointed a new Secretarial Auditor. The statutory auditor issued a qualified opinion, citing a material uncertainty about the company's ability to continue as a going concern due to cash losses, curtailed operations, and liquidity stress. Key issues include non-compliant related-party loans (₹670.26 lakhs), unconfirmed debtor balances (₹385.46 lakhs), and unconfirmed supplier advances (₹1,251.18 lakhs). The company also faces a SEBI investigation and lacks an internal auditor, indicating severe governance and control weaknesses.
Board of Directors has approved Audited Financials results for the Halh year and year ended on 31st March, 2026
Financial Result · 31 May 2026, 1:07 am
Auditor Issues Qualified Opinion, Flags Going Concern Uncertainty for FY26 Evoq Remedies reported FY26 revenue of ₹2,675.69 lakhs and a net loss of ₹25.10 lakhs. The auditor issued a qualified opinion and highlighted a material uncertainty related to the company's ability to continue as a going concern, citing cash losses, curtailed operations, liquidity stress, and a SEBI investigation. Key qualifications include non-compliance on related party loans (₹670.26 lakhs), unconfirmed debtor balances (₹385.46 lakhs), and unconfirmed supplier advances (₹1,251.18 lakhs). The financial impact of these qualifications is not determinable. The board also appointed a new Secretarial Auditor.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held today i.e. ....
Outcome · 31 May 2026, 1:03 am
Evoq Remedies FY26 Audit Flags Significant Governance and Going Concern Risks Evoq Remedies' FY26 audited results received a qualified opinion with a material uncertainty on its going concern status. Auditors flagged multiple severe issues, including cash losses, curtailed operations, and persistent failure to pay statutory dues. Key qualifications include non-compliant related party loans of ₹670.26 lakhs, unconfirmed debtor balances of ₹385.46 lakhs, and unconfirmed supplier advances of ₹1,251.18 lakhs. The company is also under SEBI investigation regarding the integrity of its financials and use of preferential issue proceeds, posing significant unquantifiable risks.
Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) ....
Rescheduled / Cancelled · 30 May 2026, 5:30 am
Evoq Remedies Reschedules Board Meeting for FY26 Financial Results Evoq Remedies has rescheduled its Board of Directors meeting from 27th May'26 to 30th May'26 at 4:00 PM. The primary agenda is to consider and approve the audited financial results for the half-year and full-year ended 31st Mar'26, along with the Auditor's Report. The meeting will take place at the company's registered office in Ahmedabad. Any other items will be discussed with the permission of the Chairperson.
Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Intimation · 14 May 2026, 5:30 am
Evoq Remedies Board Meeting on 14th May'26 to Approve Financial Results Evoq Remedies Limited (BSE: 543500) will hold a Board of Directors meeting on 14th May'26. The key agenda item is the consideration and approval of the audited financial results for the half-year and full-year ended 31st Mar'26. The meeting will also include the Auditor's Report and any other matters permitted by the Chairperson.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 01 May 2026, 12:03 am
Evoq Remedies Confirms Non-Applicability of Large Corporate Framework Evoq Remedies Limited (EVOQ) has confirmed to the BSE that it does not qualify as a Large Corporate under SEBI's framework for fund-raising via debt securities. In its filing on 30th Apr'26, the company stated it has nil outstanding borrowings as of 31st Mar'26. Consequently, the mandatory borrowing requirements and associated credit rating stipulations under the SEBI circulars are not applicable to the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth Narendrabhai Patel
Acquisition/ Disposal of Shares · 24 Oct 2025, 10:50 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth Narendrabhai Patel
Acquisition/ Disposal of Shares · 23 Oct 2025, 8:22 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Payal Patel
Acquisition/ Disposal of Shares · 23 Oct 2025, 2:43 pm
Integrated Filling (Finance)
Others (Uncategorized) · 11 Oct 2025, 1:24 am
Financial Result fpr half year ended on 30th September 2025
Financial Result · 11 Oct 2025, 1:19 am
Outcome of Board Meeting hel today i.e. 10th October 2025
Outcome · 11 Oct 2025, 1:13 am
Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/10/2025 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Intimation · 09 Oct 2025, 5:30 am
Voting Results of the Annual General Meeting held on 17th September, 2025
Annual General Meeting · 20 Sept 2025, 1:30 am
Scrutinizer Report of the Annual General Meeting of the Company held on 17th September, 2025.
Annual General Meeting · 20 Sept 2025, 1:26 am
Outcome and Summary of the Annual General Meeting held today i.e. 17th September, 2025.
Annual General Meeting · 18 Sept 2025, 12:11 am
Annual Report for the Financial Year 2024-25
Others (Uncategorized) · 26 Aug 2025, 10:11 pm
Intimation of the Annual General Meeting to be held on 17th September, 2025
Annual General Meeting · 26 Aug 2025, 10:08 pm
Outcome of the Board Meeting held on 26th August, 2025
Change in Auditor · 26 Aug 2025, 10:03 pm
Outcome of the Board Meeting held on 26th August, 2025.
Others (Uncategorized) · 26 Aug 2025, 10:02 pm
Intimation for Withdrawal of proposed preferential issue.
Intimation · 22 Aug 2025, 1:16 am